Prepubertal-Onset Vulvar Lichen Sclerosus: TheImportance of Maintenance Therapy in Long-Term Outcomes
被引:23
|
作者:
Ellis, Elizabeth
论文数: 0引用数: 0
h-index: 0
机构:
Womens & Childrens Hosp, Dept Dermatol, North Adelaide, SA 5006, AustraliaWomens & Childrens Hosp, Dept Dermatol, North Adelaide, SA 5006, Australia
Ellis, Elizabeth
[1
]
Fischer, Gayle
论文数: 0引用数: 0
h-index: 0
机构:
Womens & Childrens Hosp, Dept Dermatol, North Adelaide, SA 5006, Australia
Univ Sydney, Dept Dermatol, Sydney, NSW 2006, AustraliaWomens & Childrens Hosp, Dept Dermatol, North Adelaide, SA 5006, Australia
Fischer, Gayle
[1
,2
]
机构:
[1] Womens & Childrens Hosp, Dept Dermatol, North Adelaide, SA 5006, Australia
[2] Univ Sydney, Dept Dermatol, Sydney, NSW 2006, Australia
BackgroundThere is sufficient published data on induction treatment with potent topical corticosteroid (TCS) in childhood vulvar lichen sclerosus (VLS) but limited data on long-term management. VLS has been shown to extend beyond menarche and repercussions of suboptimal long-term control may be devastating and permanent. This single-center retrospective study reviewed outcomes of long-term treatment using individualized regimens with target outcome of complete objective normality. MethodsForty-six girls with prepubertal-onset VLS were studied for demographic data, previous treatment, induction and maintenance treatment, clinical response and compliance. Photographic records were available for all patients. The cohort was divided into two groups: adherent (using treatment all or most of the time) and non-adherent (using treatment some or less of the time). ResultsTwenty-six patients (56%) had received prior treatment however only three had achieved disease control using daily potent TCS. Twelve patients (26%) had scarring on presentation. All achieved initial objective disease suppression with induction treatment using potent TCS. Thirty-one of 33 adherent patients (93.93%) sustained complete disease remission with no progression or scarring. In contrast, 1 of the 13 nonadherent patients (8%) achieved complete disease remission (p<0.001), 9 of the 13 (69.23%) experienced disease progression (p<0.001) and 3 of the 13 (23%) developed scarring during follow-up. Those with established scarring on presentation did not recover with treatment. ConclusionOur data support previous studies regarding initial treatment with potent TCS but additionally suggest maintenance treatment with individualized regimens that achieve objective normality in addition to symptom control provide optimal outcomes.